Aeromonas hydrophila Vaccine, Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied under model designation AHV-IA-250 as a formalin-inactivated, aluminium hydroxide-adjuvanted whole-cell antigen concentrate. The liquid API is standardized to a pre-inactivation antigenic density equivalent to 1×10¹⁰ CFU/mL and a post-neutralization free formaldehyde content not exceeding 0.05%. The material is intended solely as a starting component for downstream veterinary dosage form manufacture; it is not a finished parenteral product and must be aseptically processed or terminal-sterilized only after validation in the final matrix. The antigen suspension is filled into 250 mL, 500 mL, and 1000 mL polypropylene containers with bromobutyl stoppers, nitrogen-flushed to reduce oxidative denaturation of lipopolysaccharide and flagellar epitopes. For tablets, capsules, powders, granules, premixes, and oral solutions, the liquid API is converted to a dried or diluted intermediate using processes selected to preserve immunoreactivity against O-antigen, H-antigen, and outer membrane protein targets.

What Constitutes a Robust Inactivation and Antigen Integrity Profile?

Production of AHV-IA-250 begins with submerged culture in tryptic soy broth supplemented with 0.2% yeast extract at 28°C under constant aeration to late logarithmic phase, when aerolysin, flagellin, and lipase-associated antigen expression is highest. The culture is inactivated using formaldehyde at 0.3% v/v for 24 h at 37°C with continuous mixing; the reaction is quenched with sodium metabisulfite 0.1% w/v. Inactivation completeness is verified by two sequential passages in tryptic soy broth at 25°C for 14 days; any batch showing turbidity is rejected. Antigen integrity after inactivation is measured by indirect ELISA using convalescent catfish and rabbit anti-whole-cell sera; the ratio of post-inactivation to pre-inactivation optical density is controlled at ≥0.80. This threshold is maintained because excessive formaldehyde crosslinking can mask heat-labile conformational epitopes, particularly aerolysin and protease exotoxins, and thereby reduce neutralizing antibody responses in challenge trials. The seed strain is a nonhemolytic, cytochrome oxidase-positive isolate confirmed by 16S rRNA sequencing; extraneous agent testing follows manufacturer-validated methods consistent with USDA veterinary biologics requirements.

Release testing for model AHV-IA-250 is structured around parameters relevant to all seven target dosage forms. The liquid concentrate is controlled for pH, aluminium content, residual formaldehyde, bacterial endotoxin, absence of viable Aeromonas, antigenic mass, and relative antigenicity. These parameters define the operating window for downstream formulators; deviation in any one parameter changes adsorption equilibrium, compressibility, or injectable safety margin.

When Tableting Forces Require Lyophilization or Spray Drying

The liquid API cannot be directly compressed into tablets or filled into hard-shell capsules because the 60–70% water content and aluminium hydroxide gel produce poor powder flow and high interparticle adhesion. Lyophilization in the presence of 5.0% mannitol and 1.0% glycine yields a friable cake with residual moisture ≤2.0%; the cake is milled through a 0.5 mm screen and blended with microcrystalline cellulose, anhydrous lactose, and sodium starch glycolate. Direct-compression tablet runs on a rotary press equipped with 8 mm round punches have shown acceptable ejection force when magnesium stearate is limited to 0.5 wt%; higher lubricant levels prolong disintegration beyond 15 min in 0.1 N hydrochloric acid. For oral powders and premixes, spray drying at inlet 110°C and outlet 55°C produces a particle size distribution where 90% of particles are below 125 μm, suitable for blending with corn cob, calcium carbonate, or silica carriers. The critical process conflict is thermal degradation of flagellin epitopes above 60°C product temperature; therefore, outlet temperature is maintained as the controlling parameter rather than inlet temperature. Published data for aerosolized drying of this specific antigen is limited; feasibility batches should be confirmed by ELISA antigen recovery before scale-up.

No compendial potency unit exists for Aeromonas hydrophila vaccines; dosing is therefore expressed as antigenic mass or as a relative potency index against a manufacturer reference. In published challenge studies, injectable bacterins are administered intraperitoneally at volumes of 0.05–0.2 mL per fish for fingerlings of 10–30 g, with revaccination after 14–21 days; oral and immersion routes require substantially higher antigen loads because of dilution in pond water and degradation in the anterior gut. For tablets, capsules, and premixes intended for feed delivery, the final inclusion rate should be calibrated by ELISA antigen recovery and by agglutination titre against standardized whole-cell antigen; a fixed mg/kg dosage is unreliable without specification of post-processing antigenicity. Solutions may be delivered as bath immersion at dilutions between 1:10 and 1:100 v/v, but water exchange volume, organic load, and temperature must be controlled because inactivated bacterial cells settle and adsorb to organic particulates within 30–60 min. The product is not recommended for species or production classes with uncharacterized immune ontogeny without preliminary dose titration.

Residual Formaldehyde, Endotoxin, and Sterility Boundaries Are Linked Across Dosage Forms

Formaldehyde is used as the inactivation agent, so downstream manufacturers must verify that residual levels do not compromise the safety of parenteral or mucosal products. The liquid API is released with free formaldehyde not exceeding 0.05%, a limit compatible with a 0.1 mL injectable dose after dilution; higher residual content has been associated with injection-site myositis in cyprinids. Bacterial endotoxin is controlled at ≤500 EU/mL in the concentrate; for injectable formulations, the final product must meet the lower limit appropriate for the target species and route, typically below 5 EU/kg body weight per single systemic dose. Tablets and capsules introduce no additional microbial risk if dried intermediates are stored below 25°C and 30% relative humidity; however, powders and premixes exposed to high-humidity environments may absorb moisture and support surviving spore-former growth. Mix uniformity should therefore be verified after storage under intended warehouse conditions. Sterility of the injection product is achieved by aseptic filtration after aluminium hydroxide removal or by terminal sterilization only if heat and radiation are shown not to reduce relative antigenicity below 80%; published data for this specific configuration is limited, and the chosen method must be validated by the manufacturer.

Compared with live attenuated Aeromonas hydrophila vaccines, AHV-IA-250 eliminates the risk of persistent shedding and reversion because the antigen is non-viable and cannot replicate in the host or pond sediment. Live products require maintenance of a cold chain at −80°C or lyophilization under proprietary protectants, whereas the inactivated API can be formulated into dried oral dosage forms or liquid suspensions held at 2–8°C. Compared with subunit vaccines based on single recombinant proteins, the whole-cell antigen retains multiple immunogenic targets including O-antigen, flagellin, and extracellular enzymes; this broader antigenic repertoire is relevant for heterologous challenge, although batch-to-batch variation of complex bacterial antigens is higher than for purified subunits. Compared with autogenous bacterins, AHV-IA-250 is produced against a defined internal reference using standardized culture and inactivation parameters; autogenous products may vary in antigen density and endotoxin load because they are prepared from field isolates under farm-level processing limitations. The formulation flexibility of AHV-IA-250 differentiates it from conventional injectable-only bacterins, but it also requires downstream manufacturers to manage additional stability and compatibility risks in solid oral matrices.

Comparative Potency and Adjuvant Adsorption Variables

Antigen adsorption to aluminium hydroxide is a critical variable for injectable and oral formulations. Adsorption is typically maintained at ≥90% at pH 6.8–7.4; at pH below 6.0, desorption increases and free soluble antigen is less effectively presented to antigen-presenting cells. For oral powders, aluminium hydroxide is not required for antigen recognition by gut-associated lymphoid tissue, and its removal can reduce pellet hardness and improve wettability. However, removal of the adjuvant shifts the ratio of immunogenic to non-immunogenic antigen fractions, so relative antigenicity should be retested after any change in adsorption status. The API may be formulated with mannitol, trehalose, glycine, or polyvinylpyrrolidone as drying protectants; sorbitol should be avoided at concentrations above 5.0 wt% because it lowers the glass transition temperature and produces sticky granules during milling. Tablets produced from spray-dried API show significant hardness loss at storage above 40°C when moisture exceeds 3.0%, reflecting plasticization of the amorphous matrix. The matrix should therefore be packed with desiccant and placed in high-density polyethylene containers with a moisture barrier.

Storage of the liquid API is recommended at 2–8°C in the original nitrogen-flushed container; freezing should be avoided because aluminium hydroxide gel aggregation is irreversible at −20°C. Dried intermediates should be stored at 25°C and 30% relative humidity or lower. Compatibility limitations include avoidance of anionic surfactants above 1.0%, which may displace lipopolysaccharide from the aluminium gel, and avoidance of amine-based tablet coatings because residual formaldehyde can react with primary amines to form Schiff bases, reducing available antigen. Incompatibilities with formaldehyde-scavenging excipients such as urea, amino acids with free primary amines, and ammonium chloride should be evaluated by measuring free formaldehyde and relative antigenicity at the intended packaging condition. The API should not be irradiated for terminal sterilization unless immunoreactivity recovery is shown to be ≥80% of the unirradiated control; otherwise the antigenic mass must be increased to compensate.